ReviewFrontiers in neuroscience2023
Avenues within the gut-liver-brain axis linking chronic liver disease and symptoms.
Review in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- Cholangiocyte biology in primary sclerosing cholangitis and other cholangiopathies: pathogenesis, clinical insights, and experimental tools.Physiological reviews · 2026Review
- Brain-body interactions in systemic diseases: a survey from an imaging perspective.MedScience · 2026Review
- Obesity, Metabolic Syndrome and MASLD in Children: Inflammation as the Missing Link-A Short Narrative Review.Life (Basel, Switzerland) · 2026Review
- Mechanistic insights into the liver-brain axis during chronic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- I-FABP, citrulline and non-invasive liver dysfunction indices in patients with depression - cross-sectional study results.BMC gastroenterology · 2026Article
- Multisystem pathology in chronic variable stress: gut-liver-brain axis disruption and the therapeutic promise of magnesium-L-theanine.Therapeutic advances in endocrinology and metabolism · 2026Review
- The liver-brain axis, from its function to preventive therapeutic strategies in diseases.Frontiers in endocrinology · 2026Review
- Unlocking cyanidin-3-glucoside potentials with green technologies: advances in extraction, bioavailability, and stability for therapeutic and non-therapeutic applications.Frontiers in nutrition · 2026Review
- Interaction of the Gut-Liver-Brain Axis and the sterolbiome with sexual dysfunction in patients with cirrhosis.Gut microbes · 2025Review
- Clinical significance and pathogenic mechanisms of fatigue in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Article
- Integrative Hepatology: Enhancing overall health to manage liver disease.Hepatology (Baltimore, Md.) · 2025Article
- Article
- N-acetylcysteine reduces the hepatic complications of social isolation stress through modulation of interleukin 1 and 6 gene expression and liver enzymes in mice.Scientific reports · 2025Article
- Fluoxetine and agomelatine mitigate anhedonic and hepatic changes in chronic restraint stress rat model.Scientific reports · 2025Article
- Major Depression as a Catalyst for Nonalcoholic Fatty Liver Disease: Insights From a Comprehensive Mendelian Randomization Study.Canadian journal of gastroenterology & hepatology · 2025Article
- Mediating role of muscle quality in the liver-brain axis: integrated analysis of CT markers of body composition, brain aging, and biomarkers.Frontiers in aging neuroscience · 2025Article
- Review
- The Gut-Liver-Brain Axis: From the Head to the Feet.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symptoms of fatigue, social withdrawal and mood disturbances are commonly encountered in patients with chronic liver disease and have a detrimental effect on patient quality of life. Treatment options for these symptoms are limited and a current area of unmet medical need. In this review, we will evaluate the potential mechanistic avenues within the gut-liver-brain axis that may be altered in the setting of chronic liver disease that drive the development of these symptoms. Both clinical and pre-clinical studies will be highlighted as we discuss how perturbations in host immune response, microbiome, neural responses, and metabolites composition can affect the central nervous system.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.